Biosimilar Medication Formulary Updates

Sep. 2025Pharmacy Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products

In ongoing efforts to improve the value and affordability of health care benefits for our members, UPMC Health Plan has implemented biosimilar medication formulary updates for denosumab, eculizumab, and ustekinumab products. Effective dates for these changes are as follows.

  • UPMC for Life (Medicare/Special Needs Plan):
    • Part D formularies effective Sept. 1, 2025
    • Part B policies effective Sept. 10, 2025
  • UPMC Health Plan (Commercial/Exchange) and UPMC for Kids (CHIP): Formularies effective Oct. 1, 2025
  • UPMC for You and UPMC CHC: Effective Oct. 1, 2025

For full details on these changes, please refer to pages 18-19 in the September 2025 edition of Provider Partner Update.

Recent Announcements

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Aug. 2026Education/Webinars

CME Webinar: Getting it Right from the Start: Identifying Patient Advanced Care Directives

Please join us for a live, CME-accredited webinar on Thursday, Oct. 15, 2026 that will educate providers on identifying advanced directives and surrogate decision makers on admission.
Aug. 2026Education/Webinars

Watch for a chance to rate your experience with UPMC Health Plan

Watch for a chance to rate your experience with UPMC Health Plan. You may be randomly selected to participate in a 2026 Press Ganey provider satisfaction survey that will begin this month.
Aug. 2026Important Notices